There are two well-known checkpoint inhibitors that have shown efficacy in relapses/refractory Hodgkin lymphoma, nivolumab and pembrolizumab, both PD-1 inhibitors. Here, John Kuruvilla, MD, FRCPC at the Princess Margaret Cancer Centre, Toronto, ON takes us through the existing data, such as efficacy, safety and remission rates.
Recorded at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017 meeting, held in Vancouver, BC, Canada.
Checkpoint inhibitors in Hodgkin lymphoma
